Heidelberg Pharma AG (LTS:0QW5) GF Value Rank: 8 (As of Aug. 20, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QW5 Heidelberg Pharma AG LTS:0QW5
52 GF Score
Price €2.52
GF Value €3.07
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG GF Value Rank?

Heidelberg Pharma AG LTS:0QW5 +0.80% 52 GF Value Rank is 8 as of Aug. 20, 2026, which is 100% above its 10-year median of 4.00. GuruFocus rates LTS:0QW5 with a GF Score™ of 52/100 and a GF Value™ of €3.07 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Heidelberg Pharma AG has the GF Value Rank of 8.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Heidelberg Pharma AG GF Value Rank Related Terms


LTS:0QW5 vs VRTX, REGN, RVMD: GF Value Rank Comparison

For the Biotechnology subindustry, Heidelberg Pharma AG's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's GF Value Rank falls into.


LTS:0QW5
52GF Score
Heidelberg Pharma AG LTS:0QW5
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 8 mean?
Heidelberg Pharma AG (LTS:0QW5) has a GF Value Rank of 8 as of Aug. 20, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Heidelberg Pharma AG and its competitors. This is 100% above median its historical median of 4.00. Over the past decade, Heidelberg Pharma AG's GF Value Rank has ranged from 1.00 to 10.00.
Is Heidelberg Pharma AG's GF Value Rank too high?
Heidelberg Pharma AG's current GF Value Rank of 8 is 100% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Heidelberg Pharma AG has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's GF Value Rank compare to VRTX and REGN?
Heidelberg Pharma AG's GF Value Rank of 8 can be compared against companies in the Biotechnology industry. Historically, Heidelberg Pharma AG's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current GF Value Rank is 8, which is 100% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (LTS:0QW5) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.07, compared to a current price of €2.52 — trading 17.9% below its estimated fair value. The current GF Value Rank is 8, which is 100% above median its 10-year median of 4.00. Heidelberg Pharma AG's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Heidelberg Pharma AG (LTS:0QW5), the current GF Value Rank is 8 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heidelberg Pharma AG (LTS:0QW5) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.52 is trading 17.9% below its estimated GF Value™ of €3.07. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for LTS:0QW5:

  • GF Value Rank: 8 (100% above median its 10-year median of 4.00)
  • GF Value™: €3.07 vs. price of €2.52 (17.9% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the LTS:0QW5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Heidelberg Pharma AG Business Description

Other Exchanges HPHA:GermanyHPHA:Austria
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
52GF Score

Get the complete analysis for LTS:0QW5

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price
€3.07
GF Value